Benign essential blepharospasm
diseaseOn this page
Also known as BEBblepharospasm
Summary
Benign essential blepharospasm (MONDO:0011728) is a disease and 38 clinical trials. Top therapeutic interventions include botulinum toxin type a, cannabidiol, and daxibotulinumtoxina. A subtype of focal dystonia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 38
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | benign essential blepharospasm |
| Mondo ID | MONDO:0011728 |
| MeSH | D001764 |
| DOID | DOID:529 |
| ICD-10-CM | G24.5 |
| ICD-11 | 1127235959 |
| SNOMED CT | 59026006 |
| UMLS | C2930898 |
| MedGen | 419660 |
| GARD | 0027804 |
| Is cancer (heuristic) | no |
Also known as: BEB · benign essential blepharospasm · blepharospasm
Disease family
This is a subtype of focal dystonia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › movement disorder › extrapyramidal and movement disease › dystonic disorder › focal dystonia › benign essential blepharospasm
Related subtypes (11): anismus, cervical dystonia, focal hand dystonia, oculogyric crisis, spasmodic dystonia, craniofacial dystonia, X-linked dystonia-parkinsonism, torsion dystonia 7, dystonia 23, oromandibular dystonia, dystonia, focal, task-specific
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Botulinum Toxin Type A | Phase 3 (in late-stage trials) |
| Incobotulinumtoxina | Phase 3 (in late-stage trials) |
| Onabotulinumtoxina | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cannabidiol, Mexiletine.
Clinical trials & evidence
Clinical trials
Clinical trials: 38.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 18 |
| PHASE2 | 6 |
| PHASE4 | 5 |
| PHASE3 | 4 |
| PHASE2/PHASE3 | 3 |
| EARLY_PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06195241 | PHASE4 | RECRUITING | Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm |
| NCT00761592 | PHASE4 | COMPLETED | Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm |
| NCT01259557 | PHASE4 | COMPLETED | Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm |
| NCT03508882 | PHASE4 | COMPLETED | Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm |
| NCT03641950 | PHASE4 | COMPLETED | The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm. |
| NCT00406367 | PHASE3 | COMPLETED | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm |
| NCT00682760 | PHASE3 | COMPLETED | Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm |
| NCT01791881 | PHASE3 | COMPLETED | Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of Hugeltox Inj. in Essential Blepharospasm |
| NCT02947815 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm |
| NCT03216473 | PHASE3 | COMPLETED | Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm |
| NCT04423341 | PHASE2/PHASE3 | COMPLETED | Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm |
| NCT05618470 | PHASE2/PHASE3 | UNKNOWN | Wumeiwan Jiawei Fang Use in Patients With Blepharospasm |
| NCT07489430 | PHASE2 | NOT_YET_RECRUITING | DaxibotulinumtoxinA for Blepharospasm |
| NCT00001784 | PHASE2 | COMPLETED | Mexiletine for the Treatment of Focal Dystonia |
| NCT00234507 | PHASE2 | COMPLETED | Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm |
| NCT00411255 | PHASE2 | COMPLETED | Brain Stimulation to Treat Blepharospasm or Meige Syndrome |
| NCT00507637 | PHASE2 | TERMINATED | Blepharospasm Short Interval |
| NCT05027997 | PHASE2 | COMPLETED | Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm |
| NCT02765113 | EARLY_PHASE1 | UNKNOWN | Two Different Surgical Methods of Blepharospasm |
| NCT04939909 | EARLY_PHASE1 | UNKNOWN | Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm |
| NCT00210431 | Not specified | COMPLETED | Post Marketing Surveillance Study of Dysport |
| NCT00500799 | Not specified | COMPLETED | Brain Changes in Blepharospasm |
| NCT00535938 | Not specified | COMPLETED | MDs on Botox Utility (MOBILITY) |
| NCT01287247 | Not specified | COMPLETED | Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States |
| NCT01546805 | Not specified | UNKNOWN | Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm |
| NCT01686061 | Not specified | COMPLETED | Blepharospasm Patient Survey for Patients With Blepharospasm |
| NCT01814774 | Not specified | COMPLETED | A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm |
| NCT02245958 | Not specified | COMPLETED | A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm |
| NCT02327728 | Not specified | UNKNOWN | Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm |
| NCT02370875 | Not specified | COMPLETED | rTMS and Botulinum Toxin in Benign Essential Blepharospasm |
| NCT02577224 | Not specified | COMPLETED | An RCT of a Patient-initiated Treatment Service for BEB and HFS |
| NCT02780336 | Not specified | COMPLETED | Blepharospasm Tools |
| NCT03184597 | Not specified | UNKNOWN | HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions |
| NCT03263000 | Not specified | TERMINATED | Photic Blink Reflex in People With Blepharospasm and Increased Blinking |
| NCT03269123 | Not specified | COMPLETED | A Mechanical Device for Blepharospasm |
| NCT03938363 | Not specified | COMPLETED | Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia |
| NCT04618887 | Not specified | UNKNOWN | A Comparative Study of GPI’s DBS and Pallidotomy in the Treatment of Meige Syndrome |
| NCT05103202 | Not specified | COMPLETED | Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BOTULINUM TOXIN TYPE A | 4 | 8 |
| CANNABIDIOL | 4 | 1 |
| DAXIBOTULINUMTOXINA | 4 | 1 |
| INCOBOTULINUMTOXINA | 4 | 1 |
| MEXILETINE | 4 | 1 |
| DIPRAGLURANT | 2 | 1 |